Journal article
CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
NPJ precision oncology, Vol.7(1), pp.53-53
06/02/2023
DOI: 10.1038/s41698-023-00404-w
PMCID: PMC10238543
PMID: 37268691
Abstract
Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive radiomic image signature (pRiS) to inform survival and chemotherapy benefit using computed tomography (CT) scans from 491 stage I and II HPV-associated OPSCC, which were divided into three cohorts D-1-D-3. The prognostic performance of pRiS was evaluated on two test sets (D-2, n = 162; D-3, n = 269) using concordance index. Patients from D-2 and D-3 who received either radiotherapy alone or chemoradiation were used to validate pRiS as predictive of added benefit of chemotherapy. Seven features were selected to construct pRiS, which was found to be prognostic of overall survival (OS) on univariate analysis in D-2 (hazard ratio [HR] = 2.14, 95% confidence interval [CI], 1.1-4.16, p = 0.02) and D-3 (HR = 2.74, 95% CI, 1.34-5.62, p = 0.006). Chemotherapy was associated with improved OS for high-pRiS patients in D-2 (radiation vs chemoradiation, HR = 4.47, 95% CI, 1.73-11.6, p = 0.002) and D-3 (radiation vs chemoradiation, HR = 2.99, 95% CI, 1.04-8.63, p = 0.04). In contrast, chemotherapy did not improve OS for low-pRiS patients, which indicates these patients did not derive additional benefit from chemotherapy and could be considered for treatment de-escalation. The proposed radiomic signature was prognostic of patient survival and informed benefit from chemotherapy for stage I and II HPV-associated OPSCC patients.
Details
- Title: Subtitle
- CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
- Creators
- Bolin Song - Emory UniversityKailin Yang - Cleveland ClinicVidya Sankar Viswanathan - Emory UniversityXiangxue Wang - Nanjing University of Information Science and TechnologyJonathan Lee - Cleveland ClinicSarah Stock - Cleveland ClinicPingfu Fu - Case Western Reserve UniversityCheng Lu - Emory UniversityShlomo Koyfman - Cleveland ClinicJames S. Lewis - Vanderbilt University Medical CenterAnant Madabhushi - Emory University
- Resource Type
- Journal article
- Publication Details
- NPJ precision oncology, Vol.7(1), pp.53-53
- Publisher
- NATURE PORTFOLIO
- DOI
- 10.1038/s41698-023-00404-w
- PMID
- 37268691
- PMCID
- PMC10238543
- ISSN
- 2397-768X
- eISSN
- 2397-768X
- Number of pages
- 13
- Grant note
- Bristol Myers-Squibb; Bristol-Myers Squibb 1R43EB028736-01 / National Institute of Biomedical Imaging and Bioengineering; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) W81XWH-15-1-0558 / Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service W81XWH-20-1-0595; W81XWH-18-1-0404 / Lung Cancer Research Program W81XWH-20-1-0851; W81XWH-18-1-0440 / Prostate Cancer Research Program Kidney Precision Medicine Project (KPMP) Glue Grant R01CA249992-01A1; R01CA202752-01A1; R01CA208236-01A1; R01CA216579-01A1; R01CA220581-01A1; R01CA257612-01A1; 1U01CA239055-01; 1U01CA248226-01; 1U54CA254566-01; 1R01HL15127701A1; R01HL15807101A1 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Eli-Lilly; Eli Lilly Boehringer-Ingelheim; Boehringer Ingelheim W81XWH-21-1-0345; W81XWH-21-1-0160; IBX004121A / Peer Reviewed Cancer Research Program 1 C06 RR12463-01 / National Center for Research Resources; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) Astrazeneca; AstraZeneca
- Language
- English
- Date published
- 06/02/2023
- Academic Unit
- Radiation Oncology
- Record Identifier
- 9984696581402771
Metrics
1 Record Views